Dolly A. Parasrampuria

1.6k total citations
31 papers, 922 citations indexed

About

Dolly A. Parasrampuria is a scholar working on Pediatrics, Perinatology and Child Health, Oncology and Hematology. According to data from OpenAlex, Dolly A. Parasrampuria has authored 31 papers receiving a total of 922 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pediatrics, Perinatology and Child Health, 9 papers in Oncology and 7 papers in Hematology. Recurrent topics in Dolly A. Parasrampuria's work include Pharmaceutical studies and practices (7 papers), Drug Transport and Resistance Mechanisms (5 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Dolly A. Parasrampuria is often cited by papers focused on Pharmaceutical studies and practices (7 papers), Drug Transport and Resistance Mechanisms (5 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Dolly A. Parasrampuria collaborates with scholars based in United States, United Kingdom and Japan. Dolly A. Parasrampuria's co-authors include Kenneth E. Truitt, Leslie Z. Benet, Patrick E. Ciccone, Nobuko Matsushima, Darin D. Dougherty, Alan J. Fischman, Elijahu Livni, Thomas Spencer, Ali A. Bonab and Bertha K. Madras and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and American Journal of Psychiatry.

In The Last Decade

Dolly A. Parasrampuria

29 papers receiving 887 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dolly A. Parasrampuria United States 15 333 223 215 113 111 31 922
Deborah Panebianco United States 22 257 0.8× 64 0.3× 206 1.0× 45 0.4× 233 2.1× 64 1.4k
Stefaan Rossenu Belgium 19 113 0.3× 53 0.2× 201 0.9× 27 0.2× 153 1.4× 35 976
E. Mueller Switzerland 17 192 0.6× 100 0.4× 40 0.2× 18 0.2× 71 0.6× 40 881
Xi Yang China 15 147 0.4× 28 0.1× 55 0.3× 41 0.4× 122 1.1× 87 916
A. Le Liboux France 12 148 0.4× 115 0.5× 22 0.1× 37 0.3× 73 0.7× 18 613
Y. Le Roux France 10 127 0.4× 125 0.6× 21 0.1× 20 0.2× 60 0.5× 15 453
José J. Zamorano‐León Spain 15 229 0.7× 47 0.2× 44 0.2× 30 0.3× 167 1.5× 112 883
Partha Nandy United States 18 65 0.2× 18 0.1× 128 0.6× 25 0.2× 68 0.6× 45 950
Helena Chang United States 17 161 0.5× 22 0.1× 38 0.2× 27 0.2× 224 2.0× 36 1.3k
Giuseppe Cocco Switzerland 19 727 2.2× 13 0.1× 66 0.3× 22 0.2× 230 2.1× 109 1.3k

Countries citing papers authored by Dolly A. Parasrampuria

Since Specialization
Citations

This map shows the geographic impact of Dolly A. Parasrampuria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dolly A. Parasrampuria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dolly A. Parasrampuria more than expected).

Fields of papers citing papers by Dolly A. Parasrampuria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dolly A. Parasrampuria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dolly A. Parasrampuria. The network helps show where Dolly A. Parasrampuria may publish in the future.

Co-authorship network of co-authors of Dolly A. Parasrampuria

This figure shows the co-authorship network connecting the top 25 collaborators of Dolly A. Parasrampuria. A scholar is included among the top collaborators of Dolly A. Parasrampuria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dolly A. Parasrampuria. Dolly A. Parasrampuria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sawant‐Basak, Aarti, Shweta Urva, Jatinder Kaur Mukker, et al.. (2024). Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper. Clinical Pharmacology & Therapeutics. 116(4). 902–913. 2 indexed citations
2.
Parasrampuria, Dolly A., et al.. (2022). Single-Dose Pharmacokinetics and Metabolism of the Oral Decongestant Phenylephrine HCl in Children and Adolescents. Pulmonary Therapy. 9(1). 139–150. 3 indexed citations
3.
Parasrampuria, Dolly A., et al.. (2022). Single Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects (P14-8.001). Neurology. 98(18_supplement). 2 indexed citations
4.
Drake, Charles G., Russell K. Pachynski, Sumit K. Subudhi, et al.. (2021). Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 25(2). 219–228. 28 indexed citations
5.
Iida, Shinsuke, Takayuki Ishikawa, Chang Ki Min, et al.. (2021). Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. Annals of Hematology. 100(4). 1065–1077. 5 indexed citations
6.
Parasrampuria, Dolly A., Rajesh Bandekar, & Thomas A. Puchalski. (2020). Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective. Drug Discovery Today. 25(10). 1855–1864.
7.
Luo, Man, Saad Z. Usmani, María‐Victoria Mateos, et al.. (2020). Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. The Journal of Clinical Pharmacology. 61(5). 614–627. 12 indexed citations
8.
9.
Brown, Karen, Dolly A. Parasrampuria, Daniel Weiss, et al.. (2015). The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. Thrombosis Research. 136(4). 825–831. 29 indexed citations
10.
Parasrampuria, Dolly A., Jen‐Fue Maa, Victor Dishy, et al.. (2015). Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. Clinical Drug Investigation. 36(2). 127–136. 5 indexed citations
11.
Marbury, Thomas, Nobuko Matsushima, Shuquan Chen, et al.. (2015). Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thrombosis and Haemostasis. 113(4). 719–727. 99 indexed citations
12.
Parasrampuria, Dolly A. & Kenneth E. Truitt. (2015). Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clinical Pharmacokinetics. 55(6). 641–655. 153 indexed citations
13.
Brown, Karen, et al.. (2014). THE IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE ON THE ANTICOAGULATORY EFFECTS OF EDOXABAN. Journal of the American College of Cardiology. 63(12). A2095–A2095. 4 indexed citations
14.
Parasrampuria, Dolly A., et al.. (2007). Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic‐Controlled Extended‐Release Methylphenidate Formulation in Humans. The Journal of Clinical Pharmacology. 47(12). 1476–1488. 42 indexed citations
15.
Spencer, Thomas, Joseph Biederman, Patrick E. Ciccone, et al.. (2006). PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate. American Journal of Psychiatry. 163(3). 387–395. 160 indexed citations
16.
Parasrampuria, Dolly A., et al.. (2003). Single‐Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen‐Activated Protein Kinase Inhibitor: A First‐in‐Human Study. The Journal of Clinical Pharmacology. 43(4). 406–413. 47 indexed citations
17.
Parasrampuria, Dolly A., Marianne Lantz, Jytte L. Birnbaum, Flavio Vincenti, & Leslie Z. Benet. (2002). Effect of Calcineurin Inhibitor Therapy on P‐gp Expression and Function in Lymphocytes of Renal Transplant Patients: A Preliminary Evaluation. The Journal of Clinical Pharmacology. 42(3). 304–311. 20 indexed citations
18.
Parasrampuria, Dolly A., Marianne Lantz, & Leslie Z. Benet. (2001). A Human Lymphocyte Based Ex Vivo Assay to Study the Effect of Drugs on P-glycoprotein (p-Gp) Function1. Pharmaceutical Research. 18(1). 39–44. 28 indexed citations
19.
Hickey, Anthony J., Yuhua Tian, Dolly A. Parasrampuria, & Motoko Kanke. (1993). Biliary elimination of bromsulphthalein, phenolphthalein, and doxorubicin released from microspheres following intravenous administration. Biopharmaceutics & Drug Disposition. 14(2). 181–186. 3 indexed citations
20.
Parasrampuria, Dolly A., et al.. (1991). PERCUTANEOUS DELIVERY OF PROTEINS AND PEPTIDES USING IONTOPHORETIC TECHNIQUES. Journal of Clinical Pharmacy and Therapeutics. 16(1). 7–17. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deborah Panebianco Breakdown of academic impact, for papers by Stefaan Rossenu Breakdown of academic impact, for papers by E. Mueller Breakdown of academic impact, for papers by Xi Yang Breakdown of academic impact, for papers by A. Le Liboux Breakdown of academic impact, for papers by Y. Le Roux Breakdown of academic impact, for papers by José J. Zamorano‐León Breakdown of academic impact, for papers by Partha Nandy Breakdown of academic impact, for papers by Helena Chang Breakdown of academic impact, for papers by Giuseppe Cocco
Rankless by CCL
2026